Butylscopolamine

Butylscopolamine

Gene therapy
Clinical data
Pregnancy category	AU: B2
Routes of administration	Oral, rectal, intravenous
ATC code	A03BB01 (WHO)
Physiological data
Legal status
Legal status	AU: S2 (Pharmacy only) UK: General sales list (GSL, OTC)
Pharmacokinetic data
Bioavailability	<1%
Protein binding	Low
Elimination half-life	5 hours
Excretion	Renal (50%) and fecal
Identifiers
IUPAC name [7(S)-(1α,2β,4β,5α,7β)]-9-butyl-7-(3-hydroxy- 1-oxo-2-phenylpropoxy)-9-methyl-3-oxa- 9-azonitricyclo[3.3.1.0(2,4)]nonane
CAS Number	146-64-4
PubChem Template:Abbreviation	160883
Chemical and physical data
Formula	C21H30NO4+
Molar mass	360.467 g/mol

Butylscopolamine, also known as scopolamine butylbromide and hyoscine butylbromide is an abdominal-specific antispasmodic. It is marketed under the trade name Buscopan by Boehringer Ingelheim GmbH, Germany, who also offer a combination of butylscopolamine and acetaminophen, marketed under the name Buscopan Plus.

Butylscopolamine is used to treat pain and discomfort caused by abdominal cramps or other spasmodic activity in the digestive system. When taken orally, it cannot enter the bloodstream or otherwise leave the digestive tract, so that it is only able to affect the smooth muscles of the digestive system as it passes through. It is not an analgesic in the normal sense, since it doesn't 'mask' or 'cover over' the pain, but rather works to prevent painful cramps and spasms from occurring in the first place.

Usage

Butylscopolamine is often prescribed at a low dosage, commonly 10mg three times a day, as a means of managing some of the symptoms of Irritable bowel syndrome.

External links

• Detailed Information
• Advice about IBS